Skip to content

First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD)

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521431-37-00
Acronym
ALN-SNCA-PD-2482
Enrollment
23
Registered
2025-11-17
Start date
2025-11-20
Completion date
Unknown
Last updated
2025-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

None listed

Sponsors

Regeneron Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026